Healthcare entity
Source depth averages 21.7 original sources per story, versus 3.8 across the same-window beat baseline. Negative sentiment reaches 0% here, compared with 26% across the 911-story beat baseline for the same window. Amgen is most often covered alongside FDA, which appears in 2 of these 7 stories.
Last mentioned: Aug 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 29 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Source depth averages 21.7 original sources per story, versus 3.8 across the same-window beat baseline. Negative sentiment reaches 0% here, compared with 26% across the 911-story beat baseline for the same window. Amgen is most often covered alongside FDA, which appears in 2 of these 7 stories. The 156-day window averages about 0.3 stories each week. The busiest single day carried 2. Their average consequence score of 6.1 sits level with the 6.1 recorded across the beat in that window. market-trends accounts for 4 of the 7 tracked stories, while 2 other categories carry the remainder. Amgen appears in 7 tracked Healthcare stories published from February 22, 2026 through July 27, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 911 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amgen. Shared-story counts are live from our verified record — not editorial picks.
FDA approves Merck's Lipfendra
The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients.
Marty Makary resigns as FDA Commissioner
Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure.
Q4 2025 Preview
Analysts set expectations for oncology-driven revenue growth.
Loqtorzi Launch
Full commercial ramp-up of the first-in-class PD-1 for NPC.
Yusimry Divestiture
Sale of adalimumab biosimilar to HK King-Friend for $40M.
Cimerli Divestiture
Coherus sells its ranibizumab biosimilar to Sandoz for $170M.
Copay accumulator programs are shifting thousands in drug costs back to patients, causing financial distress and potential treatment delays. Larry Gruber’s experience with Oscar Health highlights the human toll of insurance practices that prioritize cost over care.
The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol.
Source: mynbc5.com · wjcl.com
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Amgen and NovoCure represent two extremes in healthcare delivery: a wholesale-dependent drug giant and a patient-centric device innovator. The comparison reveals how direct-to-patient models are reshaping oncology treatment accessibility and reimbursement dynamics.
Hong Kong's enterprise scheme is drawing major health firms like Amgen and Pfizer, valued at over $191.5 billion combined, to expand operations and drive innovation in biotechnology. This influx could enhance local health IT infrastructure and research capabilities, while also raising questions about regulatory alignment with global health standards. For healthcare professionals, this represents opportunities in clinical advancements and talent development amid increasing regional competition.
Source: Connor Mycroft (cn) · Connor Mycroft (hk)
Coherus BioSciences is set to report Q4 2025 results, marking a critical milestone in its transition from a biosimilar-focused firm to an innovative oncology leader. Investors are closely monitoring the commercial ramp of Loqtorzi and the market share gains of the Udenyca On-Body Injector following significant portfolio divestitures.
A growing movement in cardiovascular care is challenging the 'prescribe-first' mentality of statin therapy, emphasizing patient autonomy and shared decision-making. As clinical guidelines evolve, the healthcare industry is grappling with how to balance standardized protocols with individualized patient preferences and risk profiles.
Source: theobserver.ca · clintonnewsrecord.com
Amgen is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
